Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437589 | 0.88 | TSHR (0.39) | ALDH1A1TDP1MEN1KMT2ATSHR | |
| SCHEMBL7543839 | 0.85 | MEN1 (0.39) | ALDH1A1TDP1MEN1KMT2ATSHR | |
| SCHEMBL13403168 | 0.82 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL17935652 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TDP1MEN1KMT2ATSHR | |
| SCHEMBL13423985 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TDP1MEN1KMT2ATSHR | |
| SCHEMBL4854212 | 0.74 | ALDH1A1 (0.37) | ALDH1A1TDP1MEN1KMT2ATSHR | |
| SCHEMBL8485451 | 0.72 | — | — | |
| SCHEMBL25729216 | 0.71 | TSHR (0.41) | ALDH1A1TDP1MEN1KMT2ATSHR | |
| SCHEMBL18429071 | 0.71 | LOX (0.45) | ALDH1A1TDP1MEN1KMT2ATSHR | |
| SCHEMBL12123460 | 0.69 | ALDH1A1 (0.35) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822134-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-11-21 | — | — | US | disclosed |
| US-9556210-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SABAG-RFA LTD. (IL) | 2017-01-31 | — | — | US | disclosed |
| US-20160176903-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SABAG-RFA LTD. (IL) | 2016-06-23 | — | — | US | disclosed |
| US-20160039850-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SABAG-RFA LTD. (IL) | 2016-02-11 | — | — | US | disclosed |
| US-9156865-B2 | System for delivering therapeutic agents into living cells and cells nuclei | DELIVERSIR LTD (IL) | 2015-10-13 | — | — | US | disclosed |
| WO-2014064687-A1 | A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | DELIVERSIR LTD (IL) | 2014-05-01 | — | — | WO | disclosed |
| US-20130137755-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SEGEV LABORATORIES LIMITED (IL) | 2013-05-30 | — | — | US | disclosed |
| US-8293209-B2 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2012-10-23 | — | — | US | disclosed |
| US-20100104512-A1 | Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100092386-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | SABAG-RFA LTD. (IL) | 2010-04-15 | — | — | US | disclosed |
| WO-2008043911-A2 | DENDRITIC CHELATED COMPOUNDS, METHODS FOR MAKING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039850-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | ALDH1A1 4566/4885TDP1 1114/4885MEN1 1510/4885 |
| US-20100092386-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | ALDH1A1 4566/4885TDP1 1114/4885MEN1 1510/4885 |
| US-20130137755-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | ALDH1A1 4566/4885TDP1 1114/4885MEN1 1510/4885 |
| US-20160176903-A1 | SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI | NFATC1, KPNA2, KPNA6 | ALDH1A1 4566/4885TDP1 1114/4885MEN1 1510/4885 |
| US-20100104512-A1 | Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same | ZYX, CXCR4, ZFX | ALDH1A1 4611/4885TDP1 4286/4885MEN1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.